US tracker

S. 4472

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Health, Education, Labor, and Pensions Committee · Sen. Lisa Murkowski (R-AK)

16 July 2026 | Reported by committee (Health, Education, Labor, and Pensions, with an amendment in the nature of a substitute, without written report)

What's next: Floor scheduling (leadership decides if and when it gets a vote)

Summary: The bill would extend funding through fiscal year 2031 for federal research and development programs aimed at finding treatments for ALS and other neurodegenerative diseases, including grants from the National Institutes of Health and Food and Drug Administration as well as a public-private partnership supporting drug development. It would also add new requirements for tracking the safety and effectiveness of investigational drugs, ensure timely reporting of clinical trial safety data, require the FDA to publish five-year development plans for neurodegenerative disease treatments every five years, and mandate reports on the program's impact.

[AI-Generated]

Posted 10 September 2026

As published — the exact text this tracker posted, kept verbatim for the record

S. 4472 | Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 | Sen. Lisa Murkowski (R-AK) | Health, Education, Labor, and Pensions Committee 📅 16 July 2026 | 📋 Reported by committee (Health, Education, Labor, and Pensions, with an amendment in the nature of a substitute, without written report) What's next: Floor scheduling (leadership decides if and when it gets a vote) Summary: The bill would extend funding through fiscal year 2031 for federal research and development programs aimed at finding treatments for ALS and other neurodegenerative diseases, including grants from the National Institutes of Health and Food and Drug Administration as well as a public-private partnership supporting drug development. It would also add new requirements for tracking the safety and effectiveness of investigational drugs, ensure timely reporting of clinical trial safety data, require the FDA to publish five-year development plans for neurodegenerative disease treatments every five years, and mandate reports on the program's impact. [AI-Generated]

Look it up on Congress.gov See the full path of S. 4472

A permanent record of a post published by BillTracking's US tracker. The facts are drawn from the official record; the reference above is the lookup key on Congress.gov. Spotted an error? accuracy@billtracking.org.